Department of Medicinal Chemistry, Faculty of Pharmacy and Pharmaceutical Science, Isfahan University of Medical Science, Hezar Jerib, 817416-73461 Isfahan, Iran.
Department of Medicinal Chemistry, School of Pharmacy-International Campus, Iran University of Medical Science, Tehran, Iran.
Bioorg Chem. 2021 Sep;114:105127. doi: 10.1016/j.bioorg.2021.105127. Epub 2021 Jun 29.
In this study, a new series of quinazolinone-pyrazole hybrids were designed, synthesized and screened for their α-glucosidase inhibitory activity. The results of the in vitro screening indicated that all the molecular hybrids exhibited more inhibitory activity (IC values ranging from 60.5 ± 0.3 µM-186.6 ± 20 μM) in comparison to standard acarbose (IC = 750.0 ± 10.0 µM). Limited structure-activity relationship suggested that the variation in the inhibitory activities of the compounds affected by different substitutions on phenyl rings of diphenyl pyrazole moiety. The enzyme kinetic studies of the most potent compound 9i revealed that it inhibited α-glucosidase in a competitive mode with a Ki of 56 μM. Molecular docking study was performed to predict the putative binding interaction. As expected, all pharmacophoric moieties used in the initial structure design playing a pivotal role in the interaction with the binding site of the enzyme. In addition, by performing molecular dynamic investigation and MM-GBSA calculation, we investigated the difference in structural perturbation and dynamic behavior that is observed over α-glycosidase in complex with the most active compound and acarbose relative to unbound α-glycosidase enzyme.
在这项研究中,设计、合成了一系列新的喹唑啉酮-吡唑杂合体,并对其α-葡萄糖苷酶抑制活性进行了筛选。体外筛选结果表明,与标准阿卡波糖(IC = 750.0 ± 10.0 μM)相比,所有分子杂合体均表现出更强的抑制活性(IC 值范围为 60.5 ± 0.3 μM-186.6 ± 20 μM)。有限的构效关系表明,化合物抑制活性的变化受二苯吡唑部分苯环上不同取代基的影响。最有效的化合物 9i 的酶动力学研究表明,它以竞争性模式抑制α-葡萄糖苷酶,Ki 值为 56 μM。进行了分子对接研究以预测可能的结合相互作用。正如预期的那样,在初始结构设计中使用的所有药效团在与酶结合位点的相互作用中起着关键作用。此外,通过进行分子动力学研究和 MM-GBSA 计算,我们研究了与未结合的α-葡萄糖苷酶相比,与最活跃的化合物和阿卡波糖复合的α-糖苷酶在结构扰动和动态行为上的差异。